Interleukin-27: balancing protective and pathological immunity - PubMed (original) (raw)

Review

Interleukin-27: balancing protective and pathological immunity

Christopher A Hunter et al. Immunity. 2012.

Abstract

It has been more than 15 years since the identification of individual interleukin-27 (IL-27) and IL-27 receptor components. The last decade has seen the description of the signaling pathways engaged by IL-27, and an appreciation has emerged that this cytokine can modulate the intensity and duration of many classes of T cell responses. Here we provide an overview of the immunobiology of IL-27 and review advances in understanding the functions of individual IL-27 and IL-27 receptor subunits and the role of IL-27 in dictating the balance between protective and pathological immunity. Additionally, this cytokine has been proposed as a therapy to modify inflammatory conditions or to promote antitumor responses, and situations where experimental and clinical data sets implicate IL-27 in the outcome of disease are highlighted.

Copyright © 2012 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Impact of IL-27 on lymphocyte signaling pathways. Dimerization of gp130 and IL-27Ra engages JAK1, 2 and Tyk2 that engage the MAPK pathway and activation of multiple STATs, most notably STAT1 and STAT3. The activation of STAT1 is linked to inhibition of GATA-3 and RoRγt but upregulation of PD-L1, T-bet and IL-10. The ability to engage STAT3 is linked to increased proliferation as well as IL-10 while the MAPK pathway intersects with AHR to promote IL-10 and IL-21.

Figure 2

Figure 2

Key regulatory effects of IL-27 on T and B cells. The pro-inflammatory properties attributed to IL-27 include the development of CTL, the promotion of TFH as well as a direct ability to promote B cell production of antibodies. The regulatory activities of IL-27 includes the ability to promote expression of the inhibitory receptor PD-L1 and IL-10 production by multiple helper T cells. The ability to generate a CXCR3+ Treg population is specialized to operate at sites of TH1 inflammation while the ability to control Th2 and Th17 inflammation is due to direct inhibitory effects on GATA3 and RoRgt.

Similar articles

Cited by

References

    1. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE. T(H)17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13:711–718. - PubMed
    1. Anderson CF, Stumhofer JS, Hunter CA, Sacks D. IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol. 2009;183:4619–4627. - PMC - PubMed
    1. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, Sundar S, Sacks D. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol. 2011;186:3977–3985. - PMC - PubMed
    1. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. 2010;11:854–861. - PMC - PubMed
    1. Artis D, Johnson LM, Joyce K, Saris C, Villarino A, Hunter CA, Scott P. Cutting Edge: Early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J Immunol. 2004a;172:4672–4675. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources